Given that IMAGiC platform correlates well with high TMB in various tumor types and predicted response to checkpoint inhibitor in patients with high-MSI tumor and not responding to immunotherapy, the predictive function of the IMAGiC is thought to be at least equal or superior to PD-L1 expression. This evidence concerns the gene CD274 and neoplasm.